Also known as: 1-aminoadamantane Amantadine Amantadine hydrochloride
Amantadine has been shown to be a low affinity antagonist at the N-methyl-D-aspartate (NMDA) subtype of glutamate receptors. Overactivity of glutamatergic neurotransmission has been implicated in the generation of parkinsonian symptoms. In addition, amantadine specifically inhibits the replication of influenza A viruses at low concentrations.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Amantadine is the active ingredient of these drugs:
Austria Hong Kong Lithuania
Australia Hong Kong Netherlands New Zealand Singapore
Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):